Protagonist Therapeutics Inc Total Assets
Protagonist Therapeutics Inc total assets. Based on the latest financial reports, Protagonist Therapeutics Inc (PTGX) holds total assets worth $701.69 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Protagonist Therapeutics Inc for the company's overall valuation and market capitalisation.
Total Assets of Protagonist Therapeutics Inc (2014–2024)
Total assets of Protagonist Therapeutics Inc from 2014 to 2024. This chart illustrates how Protagonist Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Protagonist Therapeutics Inc (PTGX) share price today for real-time trading data and today's change.
Protagonist Therapeutics Inc - Asset Composition Analysis
Protagonist Therapeutics Inc Total Assets Breakdown (December 2024)
Protagonist Therapeutics Inc total assets breakdown as of December 2024. Protagonist Therapeutics Inc's total assets of $701.69 Million consist of 79.4% current assets and 20.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.1% |
| Accounts Receivable | $168.49 Million | 22.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Protagonist Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PTGX net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Protagonist Therapeutics Inc's current assets represent 79.4% of total assets in 2024, a decrease from 96.0% in 2014.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2024, down from 90.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 22.6% of total assets.
Protagonist Therapeutics Inc Competitors by Total Assets
Key competitors of Protagonist Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Protagonist Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.05 | 10.70 | 7.84 |
| Quick Ratio | 13.05 | 10.70 | 7.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $541.48 Million | $432.19 Million | $275.37 Million |
Protagonist Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Protagonist Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.90 |
| Latest Market Cap to Assets Ratio | 6.84 |
| Asset Growth Rate (YoY) | 108.1% |
| Total Assets | $744.73 Million |
| Market Capitalization | $5.09 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Protagonist Therapeutics Inc's assets at a significant premium (6.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Protagonist Therapeutics Inc's assets grew by 108.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual total assets of Protagonist Therapeutics Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $744.73 Million | +108.05% |
| 2023-12-31 | $357.95 Million | +44.38% |
| 2022-12-31 | $247.93 Million | -28.69% |
| 2021-12-31 | $347.69 Million | +7.16% |
| 2020-12-31 | $324.47 Million | +109.45% |
| 2019-12-31 | $154.92 Million | +11.07% |
| 2018-12-31 | $139.47 Million | -14.82% |
| 2017-12-31 | $163.73 Million | +74.20% |
| 2016-12-31 | $93.99 Million | +533.14% |
| 2015-12-31 | $14.85 Million | +43.74% |
| 2014-12-31 | $10.33 Million | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more